VF 001

Drug Profile

VF 001

Alternative Names: VF001; VF001-DP HD; VF001-DP LD

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Factor Therapeutics
  • Class Growth factors; Proteins
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Leg ulcer

Most Recent Events

  • 21 Dec 2016 Factor Therapeutics initiates enrolment in a phase II trial for Leg ulcer in USA
  • 01 Nov 2016 Phase-II clinical trials in Leg ulcer in USA (Intradermal) (NCT02973893)
  • 10 Oct 2016 Factor Therapeutics submits amended IND application to the US FDA for Leg ulcers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top